Phase 1 Double Blind, Placebo Controlled Study Assessing Safety and Activity Of 2 Escalating Doses of hMaxi-K Gene Transfer By Direct Injection Into the Bladder Wall In Female Subjects With OAB
Latest Information Update: 12 Feb 2020
At a glance
- Drugs Maxi-K gene therapy (Primary)
- Indications Detrusor instability; Overactive bladder
- Focus Adverse reactions
- Acronyms ION-3
- Sponsors Ion Channel Innovations; Urovant Sciences
- 04 Feb 2020 According to an Urovant Sciences Media Release, data were published online in Neurology and Urodynamics, and Dr. Eric Rovner is the lead author.
- 04 Feb 2020 Results presented in an Urovant Sciences Media Release.
- 03 Mar 2017 Status changed from recruiting to active, no longer recruiting.